Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 43, Issue 3, 1999, Pages 193-198

  Ikeda, Tadasu ^a   Iwata, Keiko ^a   Tanaka, Yasushi ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Aldose reductase; Cardiovascular autonomic neuropathy; CV(R R); Epalrestat

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; EPALRESTAT;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC NEUROPATHY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HUMAN; LONG QT SYNDROME; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; QT INTERVAL; RR INTERVAL;

AGED; AGED, 80 AND OVER; ALDEHYDE REDUCTASE; AUTONOMIC NERVOUS SYSTEM DISEASES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; RHODANINE; STATISTICS, NONPARAMETRIC; THIAZOLIDINES;

EID: 0032929503     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(99)00015-7     Document Type: Article

References (15)

1. Ewing D.J., Clarke B.F. Autonomic neuropathy: its diagnosis aud prognosis. Clin. Endocrinol. Metabol. 15:1986;855-888.
2. Kahn J.K., Sisson J.C., Vinik A.I. QT interval prolongation and sudden cardiac death in diabetic autonomic neuropathy. J. Clin. Endocrinol. Metabol. 64:1987;751-754.
3. Chambers J.B., Sampson M.J., Sprigings D.C., Jackson G. QT prolongation on the electrocardiogram in diabetic autonomic neuropathy. Diabetic Med. 7:1990;105-110.
4. Ewing D.J., Boland O., Neilson J.M.N., Cho C.G., Clarke B.F. Autonomic neuropathy: QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia. 34:1991;182-185.
5. Wheeler T., Watkins P.J. Cardiac denervation in diabetes. Br. Med. J. 4:1973;584-586.
6. Ewing D.J., Martyn C.N., Young R.J., Clarke B.F. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 8:1985;491-498.
7. Pfeifer M.A., Weinberg C.R., Cook D., Best J.D., Reenan A., Halter J.B. Differential changes of autonomic nervous system function with age in man. Am. J. Med. 75:1983;249-258.
8. O'Brien I.A.D., O'Hare P., Corrall R.J.M. Heart rate variability in healthy subjects: effect of age and the derivation of normal ranges for tests of autonomic function. Br. Heart J. 55:1986;348-354.
9. Fagius J., Brattberg A., Jameson S., Berne C. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia. 28:1985;323-329.
10. Jaspan J.B., Towle V.L., Maselli R., Herold K. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism. 35(Suppl. 1):1986;83-92.
11. Jaspan J.B., Herold K., Bartkus C. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy. Am. J. Med. 79(Suppl. 5A):1985;24-37.
12. Giogliano D., Marfella R., Quatraro A. et al. Torlestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial. Ann. Intern. Med. 118:1993;7-11.
13. Bazett H.C. An analysis of the time relations of electrocardiograms. Heart. 7:1920;353-370.
14. Schwartz P.J., Snebold N.G., Brown A.M. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. Am. J. Cardiol. 37:1976;1035-1040.
15. Schouten E.G., Dekker J.M., Meppelink P., Kok F.J., Vandenbroucke J.P., Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation. 84:1991;1516-1523.